Basilea Pharmaceutica Ltd, Allschwil

BSLN

Equity

ISIN CH0011432447 / Valor 1143244

SIX Swiss Exchange (2025-04-04)

CHF 40.15-5.97%

Basilea Pharmaceutica Ltd, Allschwil
UMushroom community rating:

5.00 1 votes No rating yet

NegativeNeutralPositive

About company

Basilea Pharmaceutica Ltd, based in Allschwil, Switzerland, is a commercial-stage biopharmaceutical company listed on the SIX Swiss Exchange under the ticker BSLN. The company specializes in the research, development, and commercialization of innovative pharmaceutical products, primarily focusing on anti-infective therapies. Basilea aims to address significant medical challenges by developing treatments for serious and life-threatening conditions. Its strategic focus on anti-infectives positions it to tackle pressing global health issues, such as antibiotic resistance and the need for effective antifungal treatments. Through its commitment to advancing medical science, Basilea seeks to provide solutions that improve patient outcomes in critical care settings.

Summarized from source with an LLMView SourceSector: Healthcare

Revenue Growth

For the first half of 2024, Basilea Pharmaceutica Ltd, Allschwil reported total revenue of CHF 76.3 million, compared to CHF 84.9 million in the first half of 2023. This included a 16.6% year-on-year increase in royalty income from Cresemba, amounting to CHF 42.8 million, and a significant 109% year-on-year increase in product revenue, which reached CHF 27.6 million.

Operating and Net Profit

Basilea Pharmaceutica Ltd, Allschwil achieved an operating result of CHF 9.3 million for the first half of 2024, down from CHF 36.9 million in the same period of 2023. The company reported a net profit of CHF 20.7 million, compared to CHF 31.8 million in the first half of 2023. This resulted in basic and diluted earnings per share of CHF 1.72 and CHF 1.61, respectively.

Increased Financial Guidance

Basilea Pharmaceutica Ltd, Allschwil has increased its financial guidance for the full year 2024. The company now expects total revenue to grow by 7% to approximately CHF 196 million and operating profit to increase by 20% to around CHF 36 million. This revised guidance reflects the continued commercial success of its products and anticipated milestone payments in the second half of 2024.

Research and Development Investment

In the first half of 2024, Basilea Pharmaceutica Ltd, Allschwil invested CHF 33.6 million in research and development, up from CHF 21.5 million in the first half of 2023. This investment was driven by preparations for the phase 3 program with fosmanogepix, preclinical profiling of BAL2026 and tonabacase, and the acquisition of the LptA inhibitor program.

Cash Flow and Debt Reduction

Basilea Pharmaceutica Ltd, Allschwil reported a positive net cash flow of CHF 17.9 million from operating activities in the first half of 2024. The company also fully repaid the remaining CHF 15.6 million of a CHF 75.0 million senior secured loan by the end of March 2024. As of June 30, 2024, Basilea's net debt stood at CHF 26.2 million, down from CHF 38.1 million a year earlier.

Summarized from source with an LLMView Source

Key figures

-6.95%1Y

6.08%3Y

-5.66%5Y

Performance

29.7%1Y

31.0%3Y

32.3%5Y

Volatility